AustralianSuper Pty Ltd Decreases Holdings in Biogen Inc. $BIIB

AustralianSuper Pty Ltd trimmed its position in shares of Biogen Inc. (NASDAQ:BIIB) by 36.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 476,812 shares of the biotechnology company’s stock after selling 274,574 shares during the quarter. AustralianSuper Pty Ltd’s holdings in Biogen were worth $83,914,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Convergence Investment Partners LLC acquired a new position in Biogen during the third quarter worth about $1,342,000. Caprock Group LLC acquired a new stake in shares of Biogen in the third quarter valued at approximately $742,000. Leuthold Group LLC acquired a new stake in shares of Biogen in the third quarter valued at approximately $3,294,000. Generali Investments Management Co LLC increased its stake in shares of Biogen by 408.2% during the 3rd quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock worth $1,397,000 after purchasing an additional 8,008 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Biogen by 9.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 67,010 shares of the biotechnology company’s stock worth $9,387,000 after purchasing an additional 5,987 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Trading Down 6.4%

Shares of Biogen stock opened at $191.37 on Friday. Biogen Inc. has a fifty-two week low of $119.18 and a fifty-two week high of $205.97. The business’s fifty day moving average is $185.15 and its two-hundred day moving average is $179.24. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The firm has a market cap of $28.25 billion, a PE ratio of 20.53, a P/E/G ratio of 1.80 and a beta of 0.19.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period last year, the company earned $3.02 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts anticipate that Biogen Inc. will post 14.21 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Stifel Nicolaus upped their target price on Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Citigroup boosted their price target on Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and upped their price objective for the company from $185.00 to $225.00 in a research report on Wednesday, April 22nd. Wedbush increased their price objective on Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research note on Thursday, April 30th. Finally, JPMorgan Chase & Co. lifted their price objective on Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a research report on Thursday, April 23rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Biogen presently has a consensus rating of “Moderate Buy” and a consensus target price of $214.23.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen said diranersen produced robust tau reductions and showed cognitive benefit signals in early Alzheimer’s disease, supporting plans to move the program into Phase 3 development. Biogen Shares Jump 10% After Advancing Alzheimer’s Tau Drug
• Positive Sentiment: Several analysts remained upbeat after the CELIA data, with buy ratings and price-target support implying Wall Street sees the tau program as more de-risked than before. Biogen Buy Rating Reiterated as CELIA Phase 2 Diranersen Data De-Risk Tau Strategy and Support Unchanged $237 Price Target
• Positive Sentiment: Biogen also completed its acquisition of Apellis Pharmaceuticals, which could strengthen near-term growth by adding commercial products and broadening the company’s revenue base. Biogen Completes Acquisition of Apellis Pharmaceuticals
• Neutral Sentiment: Biogen’s Alzheimer’s pipeline remains in focus, with additional coverage noting the company still appears likely to win approval for a subcutaneous Leqembi formulation, though the FDA timeline has been delayed. Biogen’s ‘Leqembi’ Subcutaneous Approval Still Likely Despite FDA Delay, RBC Says
• Negative Sentiment: The stock also faced some skepticism because CELIA missed its primary endpoint, which is tempering enthusiasm even as investors react positively to the biomarker and cognitive signals. Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.